Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Regardless of the stock's long term potential.
On technical analysis, good entry for investors and traders.
gl all
FB: think its safe to enter?
value is always in the entry.
gl
Still waiting!
Facebook itch:
what level is worth the risk, and possible gain if Facebook re-invents itself.
online payer system?
paypal?
social activist network?
time will tell, there is potential in this conglomerate, but at what satiable support level.
sit back and take a moment!
gl all
That would be smart. Just think support levels will continue to rise till one of the big hedge funds lose there patience (which I doubt)
There are certain stocks you trade and some you invest in, think is pure investment that is following the script to a "t".
Good time are ahead on many fronts.
Cheers
Financing will always be an issue, but unlikely to be needed for the phase 1.
As you said partnership is the goal of the CEO and will happen if positive results are published from the ongoing phase 2 trial of ict-107
Time will tell.....
Agree, positive update alone in the upcoming month or two would double pps
There maybe other short term plays but this a solid play moving forward
Costs for small phase 1 trials like this one are usually under million dollars.
They have the funding!
Only issue will be upcoming short interest
Gl
the traders will make a quick buck (if anything at all) with nwbo, as its dirt cheap........ but will be screwed in the intermediate to long term.
the future reverse split and dilution will kill any hopes on smithsons' (though i love his name) projected end points, thus the report is mute.
gl
less than 4200 shares traded.
http://www.nasdaq.com/symbol/imuc/after-hours
interesting few days.
gl
The Global Financial System Can and Will Collapse Thanks to Europe... Are You Prepared?
http://www.zerohedge.com/contributed/2012-07-24/global-financial-system-can-and-will-collapse-thanks-europe-are-you-prepared
A lot has been said about the European Crisis. I’m going to explain it all in simple terms.
In simple terms, today we are facing a Crisis that is far, far worse than 2008. Before it ends, it is quite possible that we will see the entire Western Financial System collapse and a new system put into place.
This will mean:
1.Many major banks disappearing, as well as numerous potentially lengthy bank holidays (think Argentina in 2001)
2.Multiple sovereign defaults as well as broad economic contractions and their commensurate unemployment/ civil unrest/ erasure of retirement accounts/ pensions (this process has already begun in some US municipals, e.g. San Bernandino and Stockton California as well as Harrisburg Pennsylvania).
3.Possibly new currencies being introduced or new denominations of currencies (say one new unit being worth 1,000 of the old one)
4.Massive wealth destruction to the tune of tens of trillions of Dollars (think MF Global i.e. the money is gone… only systemically… in fact we just had another such instance with PF)
5.A global contraction that will result in new political/ power structures being implemented as well as the breakup of various countries/ unions.
6.Very serious trade wars to begin (see Obama’s recent attack on China) and very possibly a real war.
If the above make you frightened, you’re not alone. As I’ve dug deeper and deeper into the inner workings of the global financial system over the past months, the information I’ve come across has only gotten worse. I’ve been holding off writing all of this because up until roughly April/May it seemed possible that the world might veer towards another outcome.
I no longer view this to be the case. I am almost certain that what I’ve written above will come to pass. I know that much of what I’ve written to you in the past could be labeled as “gloom and doom.” However, I want you to know that I do not use the words “systemic collapse” lightly. Indeed, I wish I wasn’t mentioning them now, but I’d be doing you a disservice not to bring them up because we’re well on our way towards it.
So buckle up and let’s dive in.
In order to understand why we’re at risk of the financial system collapsing, you first need to understand how the global banking system works. When you or I buy an asset (say a house, or shares in a stock, or a Treasury bond), we do so because we’re looking to increase our wealth through either capital gains or through the income that asset will pay us in exchange for us parking our capital there.
In simple terms, you’re putting/ lending your money somewhere (especially if you’re buying a bond) in the hope of increasing the value or your money.
This is not how banks work. When a bank buys something, especially a bond, it parks that bond on its balance sheet as an “asset.” It then lends money out against that asset. This in of itself is not problematic except for the fact that the financial modeling of 99% of banks base assume that sovereign bonds are “risk-free.” Put another way, these models assume that the banks will always get their money back on 100 cents on the Dollar.
Yes, you read that correctly, despite the fact that world history is replete with examples of sovereign defaults (in the last 20 years alone we’ve seen more than 15 including countries as significant as Russia, Argentina, and Brazil), most banks assume that the sovereign bonds sitting on their balance sheets are risk free.
This phenomenon occurs worldwide, but given that it will be Europe, not the US that takes the system down, I’m going to focus on European bank models/ capital ratios.
You may or may not be familiar with EU banking law. EU banks are meant to comply with Basel II which is a series of capital requirements and other specifications meant to limit systemic risk.
In terms of capital ratios, Basel II requires that EU banks have equity and Tier 1 capital equal to 6% of risk weighted assets. On paper this idea was supposed to limit bank leverage to 16 to 1 (the bank has €1 in capital or equity for every €16 in loans).
However, the term “risk weighted assets” destroys this premise because it means that the bank’s loan portfolio and ultimately its leverage ratio are based on the bank’s in house models/ assumptions concerning the risk of its loans.
Let me give you an example…
Let’s say XYZ Bank lends out €50 million to a corporation. The bank won’t necessarily claim that all €50 million is “at risk.” Instead, the bank will claim that only a percentage of this €50 million is “at risk” based on the company’s credit rating, financial records (debt to equity, etc), and the like.
Thus, based on “in-house” risk modeling, European banks could in fact lend out much, much more than the Basel II requirements would imply. Considering that both bank profits and executive compensation were/are closely tied to more lenient definitions of “risk-weighted,” (i.e. lend as much as you possibly can) it’s safe to assume that EU banks are in fact much, much more leveraged.
Indeed, according to the IMF’s “official” analysis, EU banks as a whole are leveraged at 26 to 1. I would argue that in reality many of them are well north of 30 to 1 and possibly even up to 50 or 100 to 1.
The reason I can claim this with relative certainty is because the EU housing bubbles dwarfed that of the US. In the chart below the US housing bubble is the lowest line. After it comes Britain (blue) and Italy (orange) then Ireland (green) and finally Spain (dark blue).
You can only get bubbles of this magnitude if you’re lending to literally anyone with a pulse. And you can only lend that much if your in-house risk models believe that the risk of lending to anyone with a pulse is much, much lower than reality.
Hench, EU banks are likely leveraged at much, much more than 26 to 1. Indeed, considering how leveraged and toxic US banks’ (especially the investment banks’) balance sheets became from the US housing bubble, the above chart should give everyone pause when they consider the TRUE state of EU bank balance sheets.
This fact in of itself makes the possibility of a systemic collapse of the EU banking system relatively high.
On that note, we’ve recently published a report showing investors how to prepare for this. It’s called How to Play the Collapse of the European Banking System and it explains exactly how the coming Crisis will unfold as well as which investment (both direct and backdoor) you can make to profit from it.
This report is 100% FREE. You can pick up a copy today at: http://www.gainspainscapital.com
Good Investing!
Graham Summers
PS. We also feature numerous other reports ALL devoted to helping you protect yourself, your portfolio, and your loved ones from the Second Round of the Great Crisis. Whether it’s a US Debt Default, runaway inflation, or even food shortages and bank holidays, our reports cover how to get through these situations safely and profitably.
And ALL of this is available for FREE under the OUR FREE REPORTS tab at: http://www.gainspainscapital.com
agree, seemed like someone needed to settle there books the past few days, or triggers went off when people werent looking.
nothing has changed, but support needs to be confirmed.
gl
someone ran out the door?
things didnt change, but support levels are still not confirmed.
should be an interesting wednesday morning.
gl
Where will support be?
Next leg up is around the corner, though charting pharma stocks is like using mystery 8 ball...;)
Gl
Lol, either way there is clarity in the management structure....
Things should progress fwd:
Buy Yahoo!; CEO Marissa Mayer Will Lead it Out to $20
The Street
July 23, 2012
I keep an eye on stocks that perform well on days when most of the rest of the market slumps.
I haven’t done it, but it would probably be worthwhile to track how well stocks that advance on days when the Dow drops by 100 points or more perform during the days after.
To be clear, quite a few stocks went up on Friday; almost a third of NYSE names and a full quarter of NASDAQ issues rose. In the face of a choppy trading day, a 121-point drop in the Dow and a 41-point decrease in the NASDAQ, Yahoo!(YHOO) performed relatively well.
For a stock that has stagnated for so long, the 2% gain YHOO has made since it announced the hiring of Marissa Mayer as its new CEO last Monday afternoon warrants attention. The stock picked up more than half of that upside during this past Friday’s session.
Related Articles
Cramer on Retirement: Catching Up
Amazon: Are You a Wealthy Bull or Stubborn Bear?
Penn State Hit With Heavy Penalties From NCAA
Granted, YHOO has flirted with a breakout above $16 in recent months, but it could never sustain anything north of that threshold for very long. That could be change with Mayer in charge.
So much of the response to Mayer’s hiring was just sad. I was ashamed to work in the same industry as dozens of folks who decided to trash the move on such flimsy grounds.
Of course, you had the chauvinist hacks who have done nothing but disrespect Mayer because she’s a pregnant CEO.
These self-proclaimed studs never thought to reserve judgment. Maybe Mayer is capable of multi-tasking. Maybe she’ll schedule a C-section? Maybe her husband lives in the new century and plans to share the child-rearing load. Who knows? Maybe he’ll take the lead? Maybe the happy couple has parents? Maybe they’ll hire a nanny?
What a novelty — thinking before you speak.
Where there wasn’t testosterone-fueled chauvinism, we saw more than a few snarky scribes denounce Mayer before she even set foot in the office for Day One on the job.
To his credit, John C. Dvorak held off on the insults until Day One. Over at PCMag he wrote a pathetic hatchet job discrediting Mayer because she is young, looks young and is a Yahoo! outsider. Then, accompanied by little substance to support his claim, he argued that “100 resentful executives” will stab Mayer in the back before she has a chance.
He ends his out-of-touch tirade by linking to a tweet he sent Mayer saying: “@marissamayer Congratulations AND good luck. You are going to need it.” He noted that he never heard back from her. John: It never pays to be rude. Plus, it’s not that you’re 60 years old; your attitude makes you sound older. This is not the Silicon Valley you grew up covering.
In 2007, Dvorak, then at MarketWatch, said that “Apple should pull the plug on the iPhone.” Then, in PCMag circa 2010, in a classic example of making the same mistake twice, he predicted iPad would be a “good for nothing … flop.”
Just because Yahoo! has been a disaster does not mean we should brand Mayer one until she proves otherwise.
A Bold Move Brings New Blood
Quite the contrary, YHOO becomes a buy because the company made the bold move. Other tech companies pass “seasoned executives” back and forth to fill CEO jobs. That will not end well in a world defined by brands of the young, such as Google(GOOG), Facebook(FB) and Apple(AAPL).
Young, fresh blood represents the future of the tech, Internet and new-media space, not the tired old status quo that guys who have been covering the beat for decades find routine comfort in.
But it’s not even about the number that represents your age. It’s about how you approach the business. Visionaries like Steve Jobs, who died at age 56, Jeff Bezos, 48, at Amazon.com(AMZN), Mark Pincus, 46, at Zynga(ZNGA) and Tim Westergren, 46, at Pandora(P) are ageless.
The latter three — and others like them — will carry the entrepreneurial torch for Jobs. This group, which Mayer could very well end up part of someday, will run circles around people with outdated mindsets, regardless of their dates of birth.
Once the sensationalistic dust settles, investors will focus on the early portion of Mayer’s tenure as a honeymoon period. Given this week’s modest rise in YHOO, maybe they already have. As she begins setting the groundwork for a turnaround, we’ll see more upside in the shares.
After last week’s gains, YHOO trades at a price-to-earnings ratio just below 18. It’s able to stay in the teens, as opposed to the single digits of Research in Motion(RIMM) – before it started losing money — because, relatively speaking, its remains a revenue powerhouse, it does not seem to run the immediate risk of losing money, and plenty of eyeballs see value in the company’s properties and content.
If you view the P/E ratio as I do — as less of a valuation measure and more of a gauge of investor confidence in the future — it’s easy to see why you should expect more upside in YHOO on the heels of Mayer getting the CEO gig.
Yahoo Becomes a Player Again
Despite yowls from irrelevant peanut galleries, most people who matter in Silicon Valley lauded the hire. If you survey those who remain not only relevant, but influential and life-giving in tech — venture capitalists and such — the consensus is clear: We cannot believe Yahoo! pulled this off.
In the minds of many great tech/Internet/new-media thinkers and funders, Yahoo! became a player by hiring Mayer. Union Square Ventures principal Fred Wilson said it best on his blog: “Yahoo Is No Longer Dead To Me.”
In other words, Yahoo!’s Board, by deciding to hire Mayer, but also by being able to pull it off, restored investor confidence. As a result, expect the stock to command a higher multiple in the coming months on the Mayer news alone.
Once she puts her mark on the Yahoo! — by raiding Silicon Valley companies like Google for talent, for example — expect more upside. If she goes on to execute, YHOO could become one of the decade’s top multi-bagger turnaround plays.
–Written by Rocco Pendola for TheStreet. At the time of publication, the author was long FB, P and ZNGA.
It's good to have you on board
Cheers mate
quality candidate, but a poor perception candidate for this time.
should be interesting few months
thanks for the update of ownership.
gl
ts only a pos, depending on your entry.
FB sandbagged quite a few people. tough ride!
gl mate
Nice update!
Part of there Investor Relations CD packet.
few updates.
gl
Great volume, someone wants in!
long way to go, take some basis of the books.
gl all
$4 sooner than later.........
gl
lot of support in the $3.30 region.
gl
cheers!
gl
you know my stance as a long term, as HDD has entered a critical time.
but decent entry for min 10% play, with good volume to get in and out!
cheers mate
good entry, if you have patience....
gl
anything under $5 looks pretty good!:)
who would have ever known!
gl
i am impressed!
great day!
cheers to all even those with one foot in and one foot out:)
IMUC:
$3.71
lot more room to grow.
http://stockcharts.com/h-sc/ui?s=IMUC
http://ih.advfn.com/p.php?pid=nmona&article=52797952
scheduled to join the U.S. broad-market Russell 3000®, Global and Microcap Indexes when Russell Investments reconstitutes its comprehensive set of U.S. and global equity indexes on June 25, 2012, according to a preliminary list of additions posted on June 8 on the Russell website at www.russell.com/indexes.
http://ih.advfn.com/p.php?pid=nmona&article=52812136
Chief Executive Officer of the Company will be presenting at the 2012 BIO International Convention being held June 18th - 21st, 2012, at the Boston Convention and Exhibition Center in Boston, Massachusetts.
gl
"Each Unit was sold for a purchase price of $4.90 to institutional and other accredited investors in a private placement transaction. The Warrants expire in five years, have an initial exercise price of $8.34 per full share and become first exercisable on December 15, 2012. "
excerpt...
good article:
http://bostonherald.com/business/healthcare/view/20220614life_sciences_center_mum_on_details_as_event_nears
The Massachusetts Life Sciences Center is poised to make a series of high-profile announcements at next week’s BIO conference but is keeping mum about most of them.
Susan Windham-Bannister, the center’s president and CEO, said she’ll be announcing the Massachusetts and Israeli teams that are the winners of the first round of new grants for research and development.
The center also will make an announcement involving a “very significant international collaboration” and another involving international companies and Massachusetts academic institutions, Windham-Bannister said, declining to detail either.
But if the Life Sciences Center has been reluctant to reveal its hand about next week’s news, it has been prolific in the number of events it has announced in the run-up to the conference.
Last Thursday, Windham-Bannister joined Gov. Deval Patrick at the ribbon-cutting for Navidea Biopharmaceuticals’ new offices in Andover.
On Monday, Patrick marked the opening of Thermo Fisher Scientific’s new research facility in Tewksbury.
The following day, the Life Sciences Center announced that Xenetic Biosciences, a British drug development company, plans to locate its drug-development offices in the Greater Boston area.
Then, yesterday, the center announced that Batavia Bioservices, headquartered in the Netherlands, has decided to open a U.S. facility in Woburn.
Today, Gov. Patrick is slated to attend the groundbreaking for the new Translational Center for the Cure of Diabetes at the Joslin Diabetes Center in Boston. And tomorrow, Lt. Gov. Tim Murray is scheduled to attend a ribbon-cutting at Forma Therapeutics in Watertown.
-— mszaniszlo@bostonherald.com
NeurogesX, Inc. (Nasdaq:NGSX), a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel non-opioid, pain management therapies, today announced it has received two notices of allowance from the United States Patent and Trademark Office (USPTO) for patents covering NGX-1998, the Company's next generation liquid formulation of prescription strength capsaicin.
The first notice of allowance expands on NeurogesX' current patent entitled, "Methods and Compositions for Administration of TRPV1 Agonists," and includes claims that more specifically define the components of the liquid formulation of NGX-1998. The patent issuing from this application will have a term that expires in 2024.
The second notice of allowance is for the Company's patent entitled, "Compositions and Kits for the Removal of Irritating Compounds from Bodily Surfaces." This allowance includes claims relating to methods for removing capsaicin from the body using a surfactant-free, polyethylene glycol gel, and is complementary to the NGX-1998 patent family. The patent issuing from this application will have a term that expires in 2022.
"The two notices of allowance strengthen our U.S. patent estate for NGX-1998," Ronald Martell, President and CEO, commented. "Our Phase 2 data suggest that NGX-1998's product profile, including a five-minute application for up to three months of pain relief, make it an exciting advance in pain therapy. We are continuing our efforts to move into Phase 3 clinical trials as expeditiously as possible."
As previously announced, the Company expects to meet with the U.S. Food and Drug Administration (FDA) for an End of Phase 2 meeting in the third quarter of 2012. At the meeting, NeurogesX intends to discuss a 505(b)(2) clinical development program for NGX-1998 and gain greater clarity on the level of clinical data necessary for approval of NGX-1998. After the FDA meeting, the Company anticipates it will initiate a Phase 3 clinical trial by the end of 2012.
About NeurogesX, Inc.
NeurogesX, Inc. (Nasdaq:NGSX) is a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel non-opioid, pain management therapies to address unmet medical needs and improve patients' quality of life.
The Company's lead product, Qutenza®, is currently approved in the United States and the European Union. Qutenza® is now available in the United States for the management of neuropathic pain associated with postherpetic neuralgia (PHN). In Europe, Qutenza® is being marketed by Astellas Pharma Europe Ltd. (Astellas), the European affiliate of Tokyo-based Astellas Pharma Inc., for the treatment of peripheral neuropathic pain in non-diabetic adults, either alone or in combination with other medicinal products for pain.
The Company's most advanced product candidate, NGX-1998, is a topically applied liquid formulation containing a high concentration of capsaicin designed to treat pain associated with neuropathic pain conditions such as PHN. NGX-1998 has completed three Phase 1 clinical trials and one Phase 2 clinical trial in PHN patients, and the Company believes that NGX-1998 is ready to enter Phase 3 development.
The Company's early-stage pipeline includes pre-clinical compounds which include a number of prodrugs of acetaminophen. The Company has evaluated certain of these compounds in vitro and in vivo.
Safe Harbor Statement
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the Act). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include but are not limited to statements regarding: expectations, timing and subject matter for NeurogesX' planned End of Phase 2 meeting with the U.S. Food and Drug Administration; NGX-1998 being ready for entry into Phase 3 development and the planned timing of entry of NGX-1998 into a Phase 3 clinical trial. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to: NGX-1998 may fail to demonstrate sufficient safety or efficacy in clinical trials to support further development or potential marketing approval; difficulties or delays in further clinical development of NGX-1998, including difficulties or delays in initiating Phase 3 clinical trials; adverse outcomes with respect to, or delay of, the End-of-Phase 2 meeting with the FDA; market acceptance of Qutenza in already approved indications may not be sufficient to support further pursuit of commercialization of Qutenza or could have an effect on NeurogesX' development or other plans with respect to NGX-1998; Qutenza, NGX-1998 and NeurogesX' other product candidates may have unexpected adverse side effects; delay or prevention of commercialization or development activities due to unexpected expenses or a lack of sufficient resources; and difficulties or delays in identifying potential strategic partners for Qutenza and NGX-1998 and negotiating and entering into agreements with such entities. For further information regarding these and other risks related to NeurogesX' business, investors should consult NeurogesX' filings with the Securities and Exchange Commission.
CONTACT: NeurogesX, Inc.
Stephen Ghiglieri
Executive Vice President, COO and CFO
(650) 358-3310
sghiglieri@neurogesx.com
The Ruth Group
Stephanie Carrington (investors)
(646) 536-7017
scarrington@theruthgroup.com
Victoria Aguiar (media)
(646) 536-7013
vaguiar@theruthgroup.com
spoke too soon, lets see how this holds support.
gl
NeurogesX, Inc. (Nasdaq:NGSX), a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel non-opioid, pain management therapies, today announced the Japanese Patent Office (JPO) has issued patent No. 4931128 to NeurogesX for its next generation product candidate NGX-1998, a topically applied liquid formulation of prescription strength capsaicin designed to treat pain associated with neuropathic pain conditions. The patent, entitled "Methods and Compositions for Administration of TRPV1 Agonists," will remain in effect in Japan until 2024. The issued claims include formulation, system, and kit claims.
Separately, the JPO has allowed NeurogesX patent application No. 2008-504395, entitled "Oils of Capsaicinoids and Methods of Making and Using the Same." The allowed claims relate to the composition and creation of capsaicinoid oils and oils for treating capsaicin-responsive conditions. The patent scheduled to issue from this application is expected to expire in 2026.
"We believe this issued patent enhances the value of NGX-1998 in the Japanese market in the near-term, and the allowed application enables the potential for additional future value through possible product line extension. These patents enhance our position as a leader in the development and commercialization of capsaicin based therapies," said Ronald Martell, President and CEO. "We expect these milestones will better position NeurogesX as we continue to seek potential development and commercial partners for major global markets."
The issuance of Japanese patent No. 4931128 for NGX-1998 follows the notice of patent allowance the Company received in February 2012. In April 2011, NeurogesX was granted patent protection for NGX-1998 in the United States under an identically titled patent having a term that extends to 2027. A similar patent application is under review in Europe.
About NeurogesX, Inc.
NeurogesX, Inc. (Nasdaq:NGSX) is a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel non-opioid, pain management therapies to address unmet medical needs and improve patients' quality of life.
The Company's lead product, Qutenza®, is currently approved in the United States and the European Union. Qutenza® is now available in the United States for the management of neuropathic pain associated with postherpetic neuralgia (PHN). In Europe, Qutenza® is being marketed by Astellas Pharma Europe Ltd. (Astellas), the European affiliate of Tokyo-based Astellas Pharma Inc., for the treatment of peripheral neuropathic pain in non-diabetic adults, either alone or in combination with other medicinal products for pain.
The Company's most advanced product candidate, NGX-1998, is a topically applied liquid formulation containing a high concentration of capsaicin designed to treat pain associated with neuropathic pain conditions such as PHN. NGX-1998 has completed three Phase 1 clinical trials and one Phase 2 clinical trial in PHN patients, and the Company believes that NGX-1998 is ready to enter Phase 3 development.
The Company's early-stage pipeline includes pre-clinical compounds which include a number of prodrugs of acetaminophen. The Company has evaluated certain of these compounds in vitro and in vivo.
Safe Harbor Statement
This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the Act). NeurogesX disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Safe Harbor for forward-looking statements contained in the Act. Examples of such statements include but are not limited to statements regarding: the benefits of issuance of the NGX-1998 patent and the patent application allowance in Japan for potentially enhancing the value of NGX-1998 in the Japanese market and the Company's position as a leader in research and development of capsaicin based therapies, including through potential product line extensions, and for positioning NeurogesX in its efforts to seek development and commercial partners; and NGX-1998 being ready for entry into Phase 3 development. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to: NGX-1998 may fail to demonstrate sufficient safety or efficacy in clinical trials to support further development or potential marketing approval; difficulties or delays in further clinical development of NGX-1998, including difficulties or delays in initiating Phase 3 clinical trials; adverse outcomes with respect to, or delay of, the End-of-Phase 2 meeting with the FDA; market acceptance of Qutenza in already approved indications may not be sufficient to support further pursuit of commercialization of Qutenza or could have an effect on NeurogesX' development or other plans with respect to NGX-1998; Qutenza, NGX-1998 and NeurogesX' other product candidates may have unexpected adverse side effects; delay or prevention of commercialization or development activities due to unexpected expenses or a lack of sufficient resources; and difficulties or delays in identifying potential strategic partners for Qutenza and NGX-1998 and negotiating and entering into agreements with such entities. For further information regarding these and other risks related to NeurogesX' business, investors should consult NeurogesX' filings with the Securities and Exchange Commission.
CONTACT: NeurogesX, Inc.
Stephen Ghiglieri
Executive Vice President, COO and CFO
(650) 358-3310
sghiglieri@neurogesx.com
Additional Contacts:
The Ruth Group
Stephanie Carrington (investors)
(646) 536-7017
scarrington@theruthgroup.com
Victoria Aguiar (media)
(646) 536-7013
vaguiar@theruthgroup.com
hmmm, intersting activity!?
gl
I would hope so.....
Gl
Look for re-buying opportunity in $32 to $35 range!
value is still there, but current board will likely see new changes the coming 3 months.
gl
another aquisition, and a full circle is formed.
should benefit the company for the long haul
gl